Bridging therapy
Treatment given to keep a fast-growing cancer in check during the weeks between deciding on CAR-T (or transplant) and actually receiving it, while the cells are being manufactured or a donor found.
Aggressive lymphomas and leukaemias can progress or cause organ damage in the 3-6 weeks it takes to manufacture autologous CAR-T cells, so patients often receive bridging chemotherapy, steroids, radiotherapy to bulky sites, or bispecific antibodies; response to bridging and low disease burden at infusion predict better CAR-T outcomes and less CRS. Bridging must avoid drugs that harm T cells before apheresis and be timed so its toxicity has cleared before lymphodepletion. Its necessity is a strong argument for faster manufacturing and off-the-shelf allogeneic products; in the ZUMA-7 trial design, permitting bridging chemotherapy was a point of methodological debate.
Pages like this
not linked directly; found by shared links- TermAutologous stem cell transplant (ASCT)
Shares Apheresis (leukapheresis), Salvage therapy, ZUMA-7.
- TechnologyCell-therapy orchestration and chain-of-identity software
Shares Vein-to-vein time and manufacturing slots, CAR-T cell therapy.
- TechnologyApheresis and starting-material collection
- IdeaNon-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- TrialTRANSFORM
Shares Salvage therapy, CAR-T cell therapy.
- TargetCD70
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- PersonFrederick L. Locke
Shares ZUMA-7, CAR-T cell therapy.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.